New 3-(Dibenzyloxyphosphoryl)isoxazolidine Conjugates of N1-Benzylated Quinazoline-2,4-diones as Potential Cytotoxic Agents against Cancer Cell Lines
Molecules · 2024
DOI: 10.3390/molecules29133050 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2024. Verfasst von Magdalena Łysakowska und 4 weiteren Autor:innen. Beteiligte Einrichtung: Bioorganic Chemistry Laboratory, Faculty of Pharmacy, Medical University of Lodz, Muszynskiego 1, 90-151 Lodz, Poland. Hauptthemen laut MEDLINE: Antineoplastic Agents, Cell Proliferation. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Lodz, Jagiellonian University.
Abstract (Originalsprache)
In this study, a new series of cis and trans 5-substituted-3-(dibenzyloxyphosphoryl)isoxazolidines 16a–g were synthesized by the 1,3-dipolar cycloaddition reaction of N-benzyl-C-(dibenzyloxyphosphoryl)nitrone and selected N1-allyl-N3-benzylquinazoline-2,4-diones. All the obtained trans-isoxazolidines 16a–g and the samples enriched in respective cis-isomers were evaluated for anticancer activity against three tumor cell lines. All the tested compounds exhibited high activity against the prostate cancer cell line (PC-3). Isoxazolidines trans-16a and trans-16b and diastereoisomeric mixtures of isoxazolidines enriched in cis-isomer using HPLC, namely cis-16a/trans-16a (97:3) and cis-16b/trans-16b (90:10), showed the highest antiproliferative properties towards the PC-3 cell line (IC50 = 9.84 ± 3.69–12.67 ± 3.45 μM). For the most active compounds, induction apoptosis tests and an evaluation of toxicity were conducted. Isoxazolidine trans-16b showed the highest induction of apoptosis. Moreover, the most active compounds turned out safe in vitro as none affected the cell viability in the HEK293, HepG2, and HSF cellular models at all the tested concentrations. The results indicated isoxazolidine trans-16b as a promising new lead structure in the search for effective anticancer drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Bioorganic Chemistry Laboratory, Faculty of Pharmacy, Medical University of Lodz, Muszynskiego 1, 90-151 Lodz, Poland.
- Department of Technology and Biotechnology of Drugs, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Krakow, Poland.
ORCID-Profile: Magdalena Łysakowska, Iwona E Głowacka, Ewelina Honkisz-Orzechowska, Jadwiga Handzlik, Dorota G Piotrowska
Förderung
- Medical University of Lodz
- Jagiellonian University
Zitieren
APA
Łysakowska, M., Głowacka, I. E., Honkisz-Orzechowska, E., Handzlik, J., & Piotrowska, D. G. (2024). New 3-(Dibenzyloxyphosphoryl)isoxazolidine Conjugates of N1-Benzylated Quinazoline-2,4-diones as Potential Cytotoxic Agents against Cancer Cell Lines. Molecules. https://doi.org/10.3390/molecules29133050
Vancouver
Łysakowska M, Głowacka IE, Honkisz-Orzechowska E, Handzlik J, Piotrowska DG. New 3-(Dibenzyloxyphosphoryl)isoxazolidine Conjugates of N1-Benzylated Quinazoline-2,4-diones as Potential Cytotoxic Agents against Cancer Cell Lines. Molecules. 2024. doi:10.3390/molecules29133050
BibTeX
@article{ysakowska2024,
author = {Łysakowska, Magdalena and Głowacka, Iwona E and Honkisz-Orzechowska, Ewelina and Handzlik, Jadwiga and Piotrowska, Dorota G},
title = {New 3-(Dibenzyloxyphosphoryl)isoxazolidine Conjugates of N1-Benzylated Quinazoline-2,4-diones as Potential Cytotoxic Agents against Cancer Cell Lines},
journal = {Molecules},
year = {2024},
doi = {10.3390/molecules29133050}
}
EUVIMED